Bioline Rx Ltd ADR (NASDAQ:BLRX) has a beta value of 1.42 and has seen 1.61 million shares traded in the last trading session. The company, currently valued at $18.64M, closed the last trade at $0.21 per share which meant it lost -$0.01 on the day or -4.85% during that session. The BLRX stock price is -742.86% off its 52-week high price of $1.77 and 0.0% above the 52-week low of $0.21. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.21 million shares traded. The 3-month trading volume is 902.93K shares.
The consensus among analysts is that Bioline Rx Ltd ADR (BLRX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bioline Rx Ltd ADR (NASDAQ:BLRX) trade information
Sporting -4.85% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the BLRX stock price touched $0.21 or saw a rise of 19.23%. Year-to-date, Bioline Rx Ltd ADR shares have moved -86.37%, while the 5-day performance has seen it change -14.19%. Over the past 30 days, the shares of Bioline Rx Ltd ADR (NASDAQ:BLRX) have changed -53.28%. Short interest in the company has seen 1.06 million shares shorted with days to cover at 2.39.
Bioline Rx Ltd ADR (BLRX) estimates and forecasts
Figures show that Bioline Rx Ltd ADR shares have outperformed across the wider relevant industry. The company’s shares have lost -66.56% over the past 6 months, with this year growth rate of 84.04%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 419.01%.
3 analysts offering their estimates for the company have set an average revenue estimate of 7.72M for the current quarter. 1 have an estimated revenue figure of 792k for the next ending quarter. Year-ago sales stood 4.8M and 6.86M respectively for this quarter and the next, and analysts expect sales will grow by 60.80% for the current quarter and 419.01% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 21.53% over the past 5 years.
BLRX Dividends
Bioline Rx Ltd ADR is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Bioline Rx Ltd ADR (NASDAQ:BLRX)’s Major holders
The top two institutional holders are ALYESKA INVESTMENT GROUP, L.P. with over 1.95 million shares worth more than $1.11 million. As of 2024-06-30, ALYESKA INVESTMENT GROUP, L.P. held 2.6966% of shares outstanding.
The other major institutional holder is CVI HOLDINGS, LLC, with the holding of over 0.82 million shares as of 2024-06-30. The firm’s total holdings are worth over $0.46 million and represent 1.126% of shares outstanding.
